Conservative initial postoperative anticoagulation strategy after HeartMate 3 left ventricular assist device implantation.
Anticoagulation
HeartMate 3
LVAD
Journal
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
ISSN: 1568-5888
Titre abrégé: Neth Heart J
Pays: Netherlands
ID NLM: 101095458
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
accepted:
31
01
2022
pubmed:
6
4
2022
medline:
6
4
2022
entrez:
5
4
2022
Statut:
ppublish
Résumé
Although anticoagulation therapy is mandated after implantation of a left ventricular assist device (LVAD), postoperative bleedings and reoperations occur relatively frequently and are associated with worse outcomes. We evaluated the use of a conservative postoperative anticoagulation protocol in patients implanted with a HeartMate 3 (HM3) LVAD. In a single-centre retrospective analysis of postoperative outcomes after HM3 LVAD implantation, a standard (old) anticoagulation protocol (i.e. early, full-dose anticoagulation with low-molecular weight heparin and overlapping vitamin K antagonist) was compared with a new conservative anticoagulation protocol (i.e. slow initiation of vitamin K antagonists without overlapping heparin). Main outcomes were changes in international normalised ratio (INR), lactate dehydrogenase (LDH), bleeding and/or tamponade events requiring reoperation, length of stay and adverse events. In total, 73 patients (48 in old vs 25 in new protocol group) were evaluated. Mean age was 56 years (standard deviation 13) and most patients (78%) were males. Changes in INR and LDH in the first 14 days were similar in both groups (p = 0.50 and p = 0.997 for interaction, respectively). Number of bleeding/tamponade events requiring reoperation was lower in the new than in the old protocol group (4% vs 33%, p = 0.005). Postoperative 30-day mortality was similar, and we observed no thromboembolic events. Median (25th-75th percentiles) total length of postoperative hospital stay (27 (25-41) vs 21 (19-27) days, p < 0.001) and length of intensive care unit stay (5 (2-9) vs 2 (2-5) days, p = 0.022) were significantly shorter in the new protocol group. These retrospective data suggest that conservative slow initiation of anticoagulation therapy after HM3 LVAD implantation is associated with less bleeding/tamponade events requiring reoperation, a similar safety profile and a shorter duration of stay than the currently advised standard anticoagulation protocol.
Identifiants
pubmed: 35380415
doi: 10.1007/s12471-022-01671-1
pii: 10.1007/s12471-022-01671-1
pmc: PMC9475015
doi:
Types de publication
Journal Article
Langues
eng
Pagination
466-472Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2001 Nov 15;345(20):1435-43
pubmed: 11794191
J Am Coll Cardiol. 2011 Mar 22;57(12):1375-82
pubmed: 21414534
N Engl J Med. 2009 Dec 03;361(23):2241-51
pubmed: 19920051
Eur Heart J. 2018 Oct 1;39(37):3454-3460
pubmed: 30165521
N Engl J Med. 2019 Apr 25;380(17):1618-1627
pubmed: 30883052
J Saudi Heart Assoc. 2018 Jul;30(3):268-270
pubmed: 29989026
J Am Coll Cardiol. 2013 Dec 10;62(23):2188-96
pubmed: 23994419
Eur J Cardiothorac Surg. 2016 Sep;50(3):548-54
pubmed: 27436871
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
J Heart Lung Transplant. 2016 Jul;35(7):860-7
pubmed: 27435529
Eur J Cardiothorac Surg. 2020 Sep 1;58(3):511-518
pubmed: 32236472
N Engl J Med. 2017 Feb 2;376(5):451-460
pubmed: 28146651
Eur J Cardiothorac Surg. 2015 May;47(5):770-6; discussion 776-7
pubmed: 25820161
JACC Heart Fail. 2020 Jul;8(7):523-536
pubmed: 32535126
J Card Surg. 2020 Feb;35(2):447-449
pubmed: 31730719
J Heart Lung Transplant. 2018 May;37(5):579-586
pubmed: 29655662
J Heart Lung Transplant. 2020 Jun;39(6):518-525
pubmed: 32340871